Jyseleca

Filgotinib, the active ingredient in Jyseleca, is a Janus kinase (JAK) inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of rheumatoid arthritis and ulcerative colitis in adult patients who require disease‑modifying therapy. The drug works by selectively blocking JAK1, thereby reducing inflammatory signaling pathways involved in autoimmune conditions.

GNH USA supplies Jyseleca as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jyseleca, a Janus kinase inhibitor, is employed in inflammatory autoimmune diseases.

- Rheumatoid arthritis: reduces joint inflammation, pain, and structural damage, improving functional ability. - Ulcerative colitis: induces clinical remission and promotes mucosal healing in the colon. - Moderate to severe disease: provides an alternative when conventional DMARDs or biologics are inadequate.

Filgotinib may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Nausea - Headache - Upper respiratory tract infection - Increased liver enzymes - Diarrhea - Nasopharyngitis

Serious or Rare Side Effects: - Serious infections (e.g., tuberculosis, opportunistic infections) - Venous thromboembolism - Malignancies - Significant liver injury - Cardiovascular events - Severe hypersensitivity reactions

When prescribing Filgotinib, clinicians should consider several precautionary measures to minimize risk.

- Assess infection risk: screen for active or latent infections before initiating therapy. - Monitor liver function: perform baseline and periodic hepatic enzyme tests. - Evaluate hematology: check complete blood count regularly for anemia or neutropenia. - Consider cardiovascular status: review history of thrombotic events or cardiovascular disease. - Review vaccination status: administer necessary vaccines prior to starting treatment. - Store at ambient temperature: keep below 25 °C, protect from moisture, retain in original packaging.

Filgotinib can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase Filgotinib exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce Filgotinib effectiveness. - Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may enhance bleeding risk. - Other immunosuppressants (e.g., methotrexate): monitor for additive infection risk. - Non‑live vaccines: assess timing relative to therapy.